Company

Cancer is a leading global cause of death and emerges from healthy cells transforming into tumor cells due to genetic factors and external influences.

Despite the variety of over 100 diseases it encompasses, current treatments remain limited and often bring unwanted side effects.

We at YGION are committed to creating precision therapies eliminating tumors without harming patients. Recognizing that every patient and tumor is unique, we strive for customized treatments tailored to each patient’s specific condition.

Ygion Team

Our Leadership Team

Founded in 2022 by a group of scientific innovators, YGION has grown into an international, multidisciplinary team dedicated to tackling the challenges of cancer genomics and immunotherapy.

Wolfgang Fischl

Wolfgang Fischl, PhD

Co-Founder, Chief Executive Officer & Chief Scientific Officer

Georg Casari

Georg Casari, PhD

Co-Founder, Chief Executive Officer & Chief Operating Officer

Gottfried Himmler

Alexander Seitz, MD

Co-Founder, Advisor

Geert Mudde

Geert Mudde, PhD

Co-Founder, Chief Technology Officer

Sophie Zettl

Sophie Zettl, PhD

Chief Business Officer

Alexander Seitz

Gottfried Himmler, PhD

Co-Founder, Head of Clinical and Quality Operations

Our Partners

Kamosys Logo

From complexity to clarity: Unique therapies for unique patients.